Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study shows tofacitinib helps control psoriatic arthritis in daily life

NCT ID NCT04517669

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well the drug tofacitinib works for people with psoriatic arthritis in everyday medical practice. Over 12 months, researchers tracked 116 adults to see if the drug reduced disease activity and improved quality of life. The goal was to understand real-world effectiveness, not to test a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

116 people

The number who actually took part.

Started

May 2021

Finished

Jul 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will enroll approximately 500 patients from rheumatologists and/or PsA specialist centers in 10 countries (Belgium, Czech Republic, Denmark, Finland, France, Israel, Netherlands, Spain, Sweden, and Switzerland) over an enrollment period of 12 months. The above list of countries are anticipated to participate in this study, however additional countries may be included at a later time. Each patient will have up to 12 months of follow-up for a total study duration of 24 months. Consecutive patients attending a routine clinical visit will be invited to participate if they meet the eligibility criteria for the study and are to start on treatment with tofacitinib for active PsA.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. Patients aged ≥ 18 years 2. Moderate to severe PsA disease activity diagnosed 3. Patients for whom the physician's decision has been made to initiate treatment with tofacitinib, in usual clinical practice conditions and in compliance with the local label 4. Patients are treatment naïve to tofacitinib on the date of providing informed consent 5. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study 6. Patients on DMARDs must have not had a treatment change in the past 3 months Exclusion Criteria: Patients meeting any of the following criteria will not be included in the study: 1. Contraindications according to the Xeljanz® (tofacitinib) Prescribing Information 2. Receipt of any investigational drug within 3 months before study inclusion 3. Patient is pregnant or breastfeeding 4. Recent herpes zoster infection (within past 6 months) or history of severe disseminated herpes zoster infection 5. Active treatment for a malignancy 6. Concomitant treatment with a biological disease-modifying antirheumatic drugs (bDMARD)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriatic arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriatic arthritis

Contacts and locations

Locations

  • AZ Sint-Jan

    Bruges, 8000, Belgium

  • Algemeen Stedelijk Ziekenhuis

    Aalst, 9300, Belgium

  • Barzilai Medical Center

    Ashkelon, Israel

  • Bnai Zion Medical Center

    Haifa, 31048, Israel

  • C.H. Universitario de Vigo- Hospital Meixoeiro

    Vigo, Galicia, 36200, Spain

  • CHR Orleans

    Orléans, 45067, France

  • CHU Besançon - Hôpital Jean Minjoz

    Besançon, 25000, France

  • CHU Clermont Ferrand - Hopital Gabriel Montpied

    Clermont-Ferrand, 63000, France

  • CHU Tours - Hôpital Trousseau

    Tours, 37044, France

  • Centre Hospitalier Jean Rougier

    Cahors, 46000, France

  • Chaim Sheba Medical Center

    Ramat Gan, 52621, Israel

  • Galilee Medical Center

    Nahariya, Israel

  • Hadassah Hebrew University Medical Center - Ein Kerem

    Jerusalem, 91120, Israel

  • Hadassah University Hospital - Ein Kerem

    Jerusalem, 246000, Israel

  • Hopital Pasteur

    Nice, 6001, France

  • Hopital Purpan

    Toulouse, 31059, France

  • Hospital Quironsalud Infanta Luisa

    Seville, 41010, Spain

  • Hospital Regional Universitario de Malaga

    Málaga, 29010, Spain

  • Hospital Universitario Central de Asturias

    Oviedo, 33011, Spain

  • Hospital Universitario Puerta del Mar

    Cadiz, 11009, Spain

  • Hospital Universitario Reina Sofia

    Córdoba, 14004, Spain

  • Hospital Universitario San Cecilio

    Granada, 18012, Spain

  • Hospital Universitario Virgen Macarena

    Seville, 41009, Spain

  • Hospital Universitario Virgen de las Nieves

    Granada, 18014, Spain

  • Hospital de Especialidades de Jerez de la Frontera

    Cadiz, 11407, Spain

  • Infirmerie Protestante de Lyon

    Caluire-et-Cuire, 69300, France

  • Karolinska University Hospital, Solna

    Stockholm, Sweden

  • Lund University

    Lund, Sweden

  • Medisch Centrum Leeuwarden

    Leeuwarden, Netherlands

  • Medisch Spectrum Twente, Haaksbergerstraat

    Enschede, 7512 KZ, Netherlands

  • Norrlands University Hospital Umeå, Reumatologiska kliniken Västerbotten

    Umeå, Sweden

  • Nova Reuma Społka Partnerska

    Genk, 3600, Belgium

  • Rambam Health Care Center

    Haifa, Israel

  • Sheba Medical Center

    Ramat Gan, Israel

  • Skånes Universitetssjukhus, Malmö

    Malmö, Sweden

  • Soroka University Medical Center

    Beersheba, 84001, Israel

  • Sygehus Vendsyssel Hospital

    Hjørring, Denmark

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

  • The Baruch Padeh Medical Center - Poriya

    Tiberias, 15208, Israel

  • The Lady Davis Carmel Medical Center

    Haifa, 3436212, Israel

  • Turku University Hospital

    Turku, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.